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ARNOLD M. STRASHUN, MD, STANLEY J. GOLDSMITH, MD, FACC,
STEVEN F. HOROWITZ, MD, FACC
New York, New York
Serial gated blood pool scintigraphic monitoring of car-
diac function with both a nonimaging scintillation probe
and a conventional gamma camera-computer imaging
system was performed in 101 patients receiving doxo-
rubicin hydrochloride (Adriamycin) chemotherapy.
Comparision of probe- and camera-derived ejection
fractions (n = 287) correlated significantly (r = 0.70,
p < 0.005) as did the interstudy (n = 183) change in
ejection fraction (r = 0.76, p > 0.005). Significant dis-
cordance in probe- and camera-derived ejection fraction
change occurred in 3 (1.6%) of 183 interstudy intervals.
Average intrastudy variability of absolute probe-derived
ejection fraction was 2.9%. This variability was unre-
lated to the level of cardiac function.
Thirteen patients (13%) developed clinical cardio-
toxicity, including four at cumulative Adriamycin levels
less than 450 mg/m'. Mean absolute camera ejection
fraction declinefor these patients was 21% from baseline
evaluation, and mean absolute probe ejection fraction
decline was 22%. The minimal absolute ejection fraction
decline was 11% for patients with clinical congestive
heart failure. Eight asymptomatic patients had therapy
The anthracycline antibiotics are important antitumor agents
currently used for the treatment of leukemias, lymphomas
and numerous solid tumors. A clinical syndrome of severe
and therapeutically refractory cardiomyopathy is a side ef-
fect of doxorubicin hydrochloride (Adriamycin) adminis-
tration. The occurrence of the cardiomyopathy restricts the
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terminated before the development of clinical cardio-
toxicity after a mean decline in absolute camera ejection
fraction of 19 ± 4% (SD) and in probe ejection fraction
of 19 ± 9% into abnormal ranges (a decline in mag-
nitude equivalent to that in patients developing conges-
tive failure). None of these five asymptomatic patients
available for clinical follow-up at 6 months after ter-
mination of Adriamycin therapy subsequently developed
signsof ventricular dysfunction. The majority of patients
(83%) studied at 450 mg/m" cumulative dose levels did
not have a 15% or greater decline from baseline into the
abnormal range.
Thus, variability of a probe-derived ejection fraction
measurement was similar to that derived from a con-
ventional camera system and was within acceptable lim-
its for characterization of clinical Adriamycin cardio-
toxicity. The probe provides a less expensivealternative
method for monitoring of Adriamycin toxicity with sim-
ilar reliability to the more elaborate camera-computer
system.
(J Am Call CardioI1986;8:1082-7)
maximal tumoricidal potential of this most frequently ad-
ministered anthracycline agent (1-3). The incidence of chronic
doxorubicin toxicity has been controlled by limiting cu-
mulative doses of Adriamycin to no more than 450 to 550
mg/nf because clinical manifestations of cardiomyopathy
are infrequent below these levels (3,4). Serial determina-
tions of left ventricular ejection fraction at rest by radio-
nuclide imaging techniques utilizing single and multicrystal
gamma camera-computer systems have effectively charac-
terized dose-related myocardial depressive effects of chronic
Adriamycin chemotherapy (5,6). On the basis of analysis
of changes in ejection fraction, Alexander et al. (5) sug-
gested that radionuclide monitoring of cardiac function dur-
ing Adriamycin chemotherapy could predict the clinical on-
set of cardiotoxicity before clinical manifestations, thereby
0735-1097/86/$3.50
lACC Vol. 8, No.5
November 1986: 1082-7
STRASHUN ET AL.
MONITORING OF DOXORUBICIN CARDIOMYOPATHY
1083
avoiding subsequent development of congestive heart fail-
ure. These determinations have allowed continued thera-
peutic benefits extending beyond relative empiric dose ceil-
ings in the majority of patients.
Because of the increasing number of patients exposed to
doxorubicin and related compounds and the expense asso-
ciated with gamma camera-computer derived gated blood
pool analysis, serial monitoring is potentially limited. An
electrocardiogram-gated computerized scintillation probe
(Nuclear Stethoscope, BIOS) provides a relatively inex-
pensive means of evaluating left ventricular function (7).
Validation studies by several investigators (7-11) have
demonstrated acceptable intraoperator and interoperator
reproducibility of ejection fraction measurements with the
hand-directed, microprocessor-guided probe. This report
compares findings of conventional gated blood pool mon-
itoring with probe data obtained in 101 patients receiving
doxorubicin chemotherapy over an 18 month period.
Methods
Nuclear stethoscope cardiac probe. The hardware
package consists of a 2 inch (5.08 em) diameter X 1.5 inch
(3.81 em) deep sodium iodide crystal detector with a con-
verging collimator designed to provide a 2.75 inch (6.99
em) field of view at 1.5 inches (3.81 em) from the collimator
face. A dedicated microprocessor contains memory from
which data are collected, and then displayed on a cathode-
ray tube screen virtually instantaneously. The sensitivity of
the system exceeds usual counting rates of 60 to 70 kilo-
counts. The probe energy detection window is preset for
technetium with 20% acceptance around a 140 keV center
line.
An algorithm has been incorporated into the micropro-
cessor system to assist in positioning (8). The algorithm
utilizes stroke volume, end-diastolic channel counts and
synchrony with the electrocardiogram gating signal to iden-
tify optimal left ventricular and background sampling sites.
After the administered blood pool dose has reached equi-
librium, the probe is moved over the precordium in a raster-
like pattern until these algorithms have been maximally
fulfilled. Additional necessary variations in probe orienta-
tion are determined by the left ventricular positioning al-
gorithm in approximately 10% of patients. This additional
fine positioning of the probe presumably compensates for
anatomic variations of body habitus and cardiac rotation.
Equilibrium blood pool mode monitoring of left ventric-
ular activity was obtained in both beat to beat mode and
the gated ventricular function mode. The higher temporal
resolution gated ventricular function mode (10 ms/data point)
was selected over the lower temporal resolution beat to beat
mode (50 ms/data point) for data acquisition and clinical
analysis. Data acquisition requires 30 to 60 seconds of sam-
pling in the usual patient after labeling with an imaging dose
of 20 mCi technetium blood pool agent. By operator place-
ment of cursors on the time-activity curve display, the mi-
croprocessor derives the ejection fraction. The entire process
of probe positioning, acquisition and data determination was
obtained within 10 minutes in each patient studied.
Gated blood pool scintigraphy. Gated blood pool cam-
era acquisitions were obtained with a standard gamma cam-
era equipped with a general purpose low energy collimator.
Data collection and processing were performed with a com-
mercial minicomputer (MDS-N). Sixteen frame gated ac-
quisitions were obtained with a count density of 300,000
counts in the end-diastolic frame using a standard field of
view camera, and 500,000 counts with a large-field detector.
Acquisitions were obtained in anterior and "best septal"
left anterior oblique views. Quantitation of ejection fraction
was derived from the left anterior oblique acquisition uti-
lizing a semiautomated left venticular edge detection with
variable region of interest method and a fixed region of
interest paraventricular background determination method.
Peak end-diastolic and end-systolic frames were automati-
cally assigned for purposes of background correction and
ejection fraction analysis (MDS-A2 software).
Patient selection. The study group included 101 patients
(18 men and 83 women) with various tumor diagnoses stud-
ied over an 18 month period; their mean age was 51 years
(range 13 to 81). Interstudy time intervals were variable
(mean 87 days; range 5 to 400) and determined clinically
by the primary physician. A total of 287 probe-camera ac-
quisitions were obtained (2 to 6 paired studies per patient).
Chemotherapy was discontinued when there was significant
clinical or radionuclide evidence of cardiotoxicity. Clinical
criteria included the presence of a third heart sound, basilar
rales, pleural effusion and other signs of congestive heart
failure. Radionuclide criteria included an absolute decrease
of 15% or greater in left ventricular ejection fraction into
the abnormal range for camera ejection fraction (:::;55%)
and probe ejection fraction (:::;58%) (5). In addition, patients
with electrocardiographic signs of myocardial infarction were
not included in the data analysis.
Protocol. Probe data were acquired by a single expe-
rienced operator after injection into the patient of 20 mCi
technetium-99m blood pool agent (human serum albumin
initially, later replaced by in vivo labeled red blood cells).
Gated mode ventricular function probe data were compared
with gamma camera ejection fraction data that were inde-
pendently obtained and processed. Probe and camera com-
parison studies were performed in random sequence within
the same hour. All studies were performed at least 48 hours
after the previous administration of Adriamycin with a mean
study time of 29 ± 12 (SD) days after the prior Adriamycin
dose. Intraobserver variability of probe data was determined
in 15 patients selected at random by performing an initial
probe placement and acquisition, followed by the camera
acquisition and finally followed by a repeat probe placement
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Figure 1. Linear regression analysis of intrastudy (n = 15) vari-
ation in probe-derived left ventricular ejection fracti?n (LV~F).
Patients were restudied after repositioning of an algorithm-guided
probe at least 30 minutes after the initial acquisition.
PBEF#l
Figure 2. Regression analysiscomparingthe intrastudy variations
inabsolute probe-derived leftventricular ejection fraction (~ PBEF%)
with the level of ventricular performance expressed as the initial
ejection fraction (PBEF #1). Intrastudy variation is unrelated to
the level of cardiac function . ns = not significant.
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Figure 3. Linear regression analysis of gated blood pool ejection
fraction analysis determined by the cardiac probe (PBEF) ~nd a
conventional camera computer system (CAMEF) reveals a highly
significant correlation between the imagingand nonimaging data.
. . I. ••••
... .
• '.~ :.. : n e 287
.- .,,: .
••••• :.... y= .75x +.15
• r:0.70
p< 0.005
see =o.oe
1.0
.9
.8
.7
.6
PSEF .5
.4
.3
.2
.1
as ± 2 SO interval ejection fraction change) occurred in 103
(56%) of the 183 monitored intervals (Fig.4). Significant
augmentation (2:6% improvement in both camera ejection
fraction and probe ejection fraction) occurred in 27 (26%)
of these 103 intervals. A significant decline (2:6% decline
in camera ejection fraction and probe ejection fraction) oc-
curred in 76 (74%) of the 103 intervals. Insignificant change
(less than ± 6% variation in both camera ejection fraction
and probe ejection fraction) occurred in 58 intervals (32%).
A discordant change in probe ejection fraction defined as a
± 6% (2 SD) interval probe ejection fraction change without
a parallel significant camera ejection fraction variation of
± 6% (2 SO) occurred in 22 (12%) of the 183 intervals .
Results
Reproducibility of probe-derived ejection fraction. In
the 15 patients who were studied twice, the average change
between the two studies was 2.9% (4.1 %, SEE) for absolute
left ventricular ejection fraction (Fig. I.) Standard deviation
determination by root mean square analysis revealed that
the intrastudy variability was 3.4% for ejection fraction.
Linear regression analysis revealed no significant correlation
betwen the extent of variability of ejection fraction and
cardiac function (Fig. 2).
Serial monitoring data. Left ventricular ejection frac-
tion at rest determined from the camera and the probe were
compared in 101 patients undergoing 287 paired evalua-
tions. Individual probe data correlated with gated blood pool
studies (r = 0 .70, P > 0.005) (Fig. 3). Correlation of the
interstudy change in ejection fraction as determined both
with the camera and the probe for 183 patient intervals was
also highly significant (r = 0 .76, P > 0.005) (Fig. 3) . A
concordant probe ejection fraction and camera ejection frac-
tion change of significance from the previous study (defined
and acquisition approximately 30 minutes later. All acqui-
sitions and processing were performed by different operators
without knowledge of prior quantitative results, cumulative
Adriamycin dose received or clinical data.
Statistical analysis. Inference of significance was de-
rived from a Student distribution with two tails. Intrastudy
variability of probe-derived variables was determined by
root mean square determination of standard deviation from
repeated acquisition. A similar method previously utilized
in our laboratory determined the variability of camera-de-
rived absolute ejection fraction at rest to be ± 3% (SO).
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Figure 4. Linear regression analysis of interstudy patient data
(183 study intervals) comparing inverval absolute change in cam-
era-derived ejection fraction (camera d EF%) and cardiac probe-
derived ejection fraction (probe d EF%) in patients receiving vary-
ing doses of adriamycin at widely varying time intervals (0 to 600
days).
Serious discordant changes (directionally opposite changes
of ± 2 SD of probe ejection fraction and camera ejection
fraction, respectively) occurred in only three interstudy in-
tervals ( 1.6% ).
Aggregate ejection fraction data (n = 287) revealed no
correlation between cumulative Adriamycin dose and ab-
solute probe ejection fraction or camera ejection fraction
(Fig. 5 and 6) .
Clinical cardiotoxicity. Thirteen patients developed
clinical sign s of left ventricular dysfunction and failure dur-
ing the period of Adriamycin therapy monitoring . At the
first manifestation of left ventricular dysfunction , camera
ejection fraction for these patients ranged from 29 to 47 %
(mean 37 ± 6%; normal camera ejection fraction is 55%
or less) . The range of absolute camera ejection fraction
decline from baseline was 13 to 32% (mean 21 ± 9%).
The range of absolute probe ejection fraction decline from
baseline was 11 to 48 % (mean 22 ± 11 %). Four of the 13
patients developed clin ical ventricular dysfunction at cu-
mulative Adriamycin dose levels less than 450 mg/rn? (320 ,
365 , 400 and 425 mg/rrr ' ) . Mean camera ejection fraction
for these four patients was 33 ± 3% (range 29 to 36%) at
the time of premature development of left ventricular dys-
function ; their average baseline camera ejection fraction
(59%) was not significantly different than that of the nine
patients (60 %), developing congestive heart failure at cu-
mulative doses in excess of 450 rng/m". In these nine pa-
tient s, clinical factors necessitated continued Adriamycin
therapy exceeding the empiric dose restrictions. These nine
patients received a mean additional dose of 135 mg/rn'' (av-
erage total cumulative dose 585, range 520 to 710 ) before
termination of therapy with a mean camera ejection fraction
of 39% (range 29 to 47%) .
Twenty-four (83 %) of 29 patients studied at or beyond
the empiric cumulative Adriamycin dose ceiling of 450 mg/
m2 did not develop signs of congestive failure or the car-
diotoxicity criteria of Alexander et al.(5) of a 15% absolute
decrease of left ventricular ejection fraction into the abnor-
mal range . There were eight patients whose therapy was
terminated before the development of signs of left ventric-
ular dysfun ction because of a 15% absolute left ventricular
ejection fraction decline from baseline into the abnormal
range for both camera ejection fraction and probe ejection
fraction . Mean cumulative dose for this group was 558 ±
138 mg/rrr' (range 350 to 750). The five patients from this
group who were available for clinical follow-up at 6 months
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Figure S. Comparison of probe-derived
ejection fraction (PBEF%) and cumulative
adriamycin dose reveals no direct correla-
tion. Horizontal dashed line represents
previously determined normal range for
ejection fraction (2::58%) (8). ns = not sig-
nificant.
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Figure 6. Camera-derived ejection fraction
(CAMEF%) and cumulative adriamycin dose
reveals no direct correlation. Dashed line
signifies normal camera ejection fraction
range (~55%). ns = not significant.
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after termination of Adriamycin therapy had not developed
signs of left ventricular dysfunction. The mean baseline
camera ejection fraction was 63 ± 5% (range 55 to 70) in
these eight patients. There was no significant difference in
baseline camera ejection fraction between the two groups
fulfilling the radionuclide cardiotoxicity criteria of Alex-
ander et al. (5), those without clinical failure and those
developing clinical failure. There was no significant differ-
ence in amount of absolute decline in camera ejection frac-
tion and probe ejection fraction from baseline in the two
groups: mean decline in camera ejection fraction units with-
out development of left ventricular failure was 18.7 ± 4.2
versus 20,5 ± 8.6 for those developing clinical left ven-
tricular failure (p = NS). Mean decline in probe ejection
fraction without development of clinical signs of congestive
failure was 18.6 ± 8.9 versus 21.5 ± 10.6 for those de-
veloping failure (p = NS).
Discussion
The results of this study show that ejection fraction data
derived from gated blood pool monitoring with the cardiac
probe are reproducible and provide clinically useful data
ordinarily obtained with the more elaborate gamma camera
computer system. A clinically significant difference between
probe ejection fraction and camera ejection fraction occurred
in 3 (1.6%) of 183 study intervals. Assuming that the dif-
ference represented probe error, this difference was possibly
due to failure of the positioning algorithm to accurately
determine probe sampling sites for the left ventricle or back-
ground, or both. Another explanation would be failure of
the operator to respond to the microprocessor optical cues
for proper positioning. Finally inadvertent movement of the
patient or the probe after accurate microprocessor-guided
probe placement during subsequent data collection could
have introduced error. Microprocessor-guided operator probe
placement is a learned skill, providing a potential for error
in data collection. Nonetheless, this error was rare, because
180 (98%) of 183 intervals were concordant within the con-
fidence limits set by the variability of both system mea-
surements of ejection fraction.
Clinical significance. Comparison of probe- and cam-
era-derived ejection fraction data revealed that probe data
proved as reliable as that from the camera in predicting
cardiotoxicity: all patients developing clinical cardiotoxicity
had an 11% or greater absolute left ventricular ejection
fraction decline into the abnormal range as determined by
both camera and probe. The radionuclide cardiotoxicity cri-
teria of Alexander et al. (5) of a 15% or greater left ven-
tricular ejection fraction decline into the abnormal range did
characterize a small group of patients (n = 8) without clin-
ical manifestations of cardiotoxicity who failed to develop
subsequent clinical cardiotoxicity after discontinuation of
additional doxorubicin treatments. The criterion was not
specific for subclinical cardiotoxicity, because an equivalent
decline in left ventricular ejection fraction from baseline
also characterized those patients (n = 13) with clinically
manifested cardiotoxicity. In these patients, more frequent
radionuclide evaluation would have been necessary to better
characterize subclinical involvement as well as to predict
the critical additional dose of Adriamycin responsible for
progression of cardiotoxicity from a subclinical to a clinical
level. It is also possible that changes in loading conditions
due to dehydration, hypertension or toxic states could either
exaggerate or mask a significant decline in ejection fraction.
The unexpected significant decline of left ventricular ejec-
tion fraction with attendant congestive heart failure in four
patients at low cumulative Adriamycin doses (320,365,400
and 425 mg/rrr') further supports the need to reassess cardiac
function at earlier and more frequent intermediate dose lev-
els as well as at the empiric dose ceiling of 450 mg/rn? and
beyond. Only in this way would it be possible for patients
with increased susceptibility to the cardiotoxic side effects
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of Adriamycin to be distinguished at early treatment levels
from the majority who safely tolerate significant additional
Adriamycin therapy beyond arbitrary dose restrictions .
Limitations of the study. This report represents a ret-
rospective analysis of data rather than a structured protocol
with fixed follow-up intervals and indications for study.
Patient referrals, therefore , were based on heterogeneous
criteria individually determined by each referring physician .
The most common referral indication was routine follow-
up before the next scheduled administration of Adriamycin.
However. a changing clinical status of the patient as an
indication for study could introduce selection bias into the
data base .
Accordingly. our failure to clearly distinguish subclinical
from clinical cardiotoxicity with a criterion of measured
ejection fraction change may be explained by both the pa-
tient referral pattern and the need for more frequent radio-
nuclide assessment than was utilized in our study (mean
number of assessments per patient = 2.85 studies, mean
interval dose = 168 mg/rrr'). A less likely explanation is a
difference in precision of ejection fraction measurement ,
because the range of reproducibility of ejection fraction
measurements of the multicrystal camera-monitored first pass
technique of Alexander et al. (5) (± 4%) was essentially
equivalent to the reproducibility of either our camera-de-
rived ejection fraction (± 3%) or our probe-derived ejection
fraction ( ± 3%).
Conclusions. Because of the large number of patients
receiving Adriamycin and the demonstrated necessity to
frequently evaluate dose-related changes in cardiac function
to account for the apparent wide biologic variation in dose-
related cardiotoxicity, utilization of a small, portable and
relatively inexpensive nuclear cardiac probe offers the po-
tential for more comprehensive application of gated blood
pool monitoring. The nonimaging computerized probe ap-
pears to be an acceptable alternative to a more elaborate
and costly imaging system for monitoring the development
of subclinical doxorubicin cardiotoxicity . This study shows
that ejection fraction data derived from the Nuclear Steth-
oscope cardiac probe proved as reliable as those from the
camera in determining cardiotoxicity. Probe portability and
speed of data recovery could more easily accommodate fu-
ture studies by providing immediate ejection fraction data
at the site of chemotherapy in the oncology clinic or at the
bedside .
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